参麦注射液联合左卡尼汀治疗缺血性心肌病心力衰竭疗效观察

Effect of Shenmai Injection and Levocarnitine in Treatment of Ischemic Cardiomyopathy with Heart Failure

目的:探讨参麦注射液联合左卡尼汀治疗缺血性心肌病心力衰竭的临床疗效,并观察和分析其对心功能的改善,为临床治疗提供依据。方法:选择医院2014年1月—2015年3月缺血性心肌病心力衰竭患者136例,随机分为对照组和观察组,两组各68例,对照组进行常规治疗,观察组在对照组基础上应用参麦注射液联合左卡尼汀治疗,均连续治疗两周。主要观察治疗效果,症状或体征的改善、应用超声心动图评估治疗前后每搏心输出量(SV)、左室射血分数(LVEF)、左心室收缩末期容积(LVESV)及左心室舒张末期容积(LVEDV)等心功能指标。结果:观察组总有效率为98.53%(67/68),高于对照组92.65%(63/68),差异有统计学意义(P<0.05);观察组乏力、气促、胸闷改善率分别为86.76%(52/68)、88.24%(60/68)和83.82%(57/68),均高于对照组,差异有统计学意义(P<0.05);观察组治疗后SV和LVEF分别为(4.78±0.22)L/min和(76.10±6.93)%,均高于对照组治疗后,差异有统计学意义(P<0.05);观察组治疗后LVESV和LVEDV分别为(74.10±6.93)m L和(85.39±9.62)m L,均第于对照组治疗后,差异有统计学意义(P<0.05)。结论:参麦注射液联合左卡尼汀治疗缺血性心肌病心力衰竭具有较好的临床疗效,能够显著改善患者症状或体征,并提高患者心功能。

Objective： To explore the effect of Shenmai Injection and Levocarnitine for treatment of ischemic cardiomyopathy with heart failure.To observe and analyze the improvement of heart function and provide the basis for clinical therapy.Methods： 136 ischemic cardiomyopathy patients with heart failure were selected in the hospital from January 2014 to March 2015 and were randomly divided into the control group and the observation group,68 cases in each group. The control group was given conventional treatment and the observation group added Shenmai Injection and Levocarnitine therapy based on the control group＇s treatment.They were treated for two weeks. The effect and symptoms or signs improvement were observed and cardiac stroke volume（ SV）,left ventricular ejection fraction（ LVEF）,left ventricular end systolic volume（ LVESV） and left ventricular end diastolic volume（ LVEDV） of cardiac function were evaluated by ultrasonic cardiogram.Results： The total effective rate of observation group was 98.53%（ 67 / 68）,higher than the control group＇s 92. 65%（ 63/68） and the difference was statistically significant（ P〈0. 05）. The improvement rate of the fatigue,shortness of breath,chest tightness in the observation group were 86.76%（ 52 / 68）,88.24%（ 60 / 68） and 83.82%（ 57 / 68）,higher than those in the control group and the difference was statistically significant（ P〈0.05）. SV and LVEF of the observation group after treatment were（ 4.78±0.22） L / min and（ 76.10± 6.93） %,higher than those of the control group after treatment and the difference was statistically significant（ P〈0.05）. LVESV and LVEDV of the observation group after treatment were（ 74.10±6.93） m L and（ 85.39±9.62） m L,lower than those of the control group after treatment and the difference was statistically significant（ P〈0.05）. Conclusion： Shenmai Injection and Levocarnitine have better clinical efficacyin the treatment of ischemic cardiomyopathy heart failure,which can significantly improve patients＇ symptoms or signs and improve heart function.